Abstract

Daidzein is a naturally occurring compound belonging to the class isoflavones and found in soya beans and other legumes. Acute oral toxicity was performed as per OECD guideline (TG 423) with slight modifications. A repeated dose toxicity study was carried out as per OECD guideline (TG 407). In-silico toxicity such as AMES toxicity, carcinogenicity, mutagenicity, immunotoxicity, hepatotoxicity, skin irritation, reproductive effect, rat and mouse toxicity, LD_50, hERG I, II inhibitor and minnow toxicity were predicted using online servers and tools. In an acute oral toxicity study, daidzein did not show any mortality in experimental animals. The No Observed Adverse Effect Level (NOAEL) of daidzein was found to be above 5000 mg/kg. 28 days treatment of diadzein at all doses did not show changes in hematology parameters, clinical biochemistry and kidney function parameters. Gross necropsy or histopathology of important organs showed no signs of toxicity. In-silico predicted parameters also demonstrated risks ranging from low to a nontoxic level. Thus, daidzein was found to be safe in acute and repeated oral dose toxicity studies at all selected doses. In-silico study also indicated that daidzein is safe.

 抽象的

大豆黄酮是一种天然存在的化合物，属于异黄酮类，存在于大豆和其他豆类中。急性口服毒性按照 OECD 指南 (TG 423) 进行，并略有修改。根据 OECD 指南 (TG 407) 进行了重复剂量毒性研究。使用在线服务器和工具预测了计算机毒性，例如 AMES 毒性、致癌性、致突变性、免疫毒性、肝毒性、皮肤刺激、生殖影响、大鼠和小鼠毒性、LD _50、 hERG I、II 抑制剂和米诺鱼毒性。在一项急性口服毒性研究中，大豆黄酮在实验动物中没有显示出任何死亡情况。黄豆苷元的未观察到不良效应水平 (NOAEL) 高于 5000 mg/kg。所有剂量的二黄酮治疗 28 天，血液学参数、临床生化和肾功能参数均未出现变化。重要器官的大体尸检或组织病理学显示没有毒性迹象。计算机预测参数还证明了风险范围从低到无毒水平。因此，在所有选定剂量的急性和重复口服剂量毒性研究中，发现黄豆苷元是安全的。计算机模拟研究还表明，大豆黄酮是安全的。